Common Drug Review *

Submission Status

Canadian Agency for Drugs and Technologies in Health

Product:	Targin
Generic Name:	oxycodone HCl / naloxone HCl
Manufacturer:	Purdue Pharma
Indication:	Moderate to severe pain and relief of opioid-induced constipation
Submission Type:	Initial
Date Submission Received:	2010-Nov-30
Date NOC Issued:	2009-Dec-16
Targeted CEDAC Meeting:	2011-May-18
Priority Review Granted:	Not Granted

	Phase	Target Time (Business Days)	Target Date **	Actual CDR Date	Comments
1	Submission deemed complete	5	2010-Dec-07	2010-Dec-10	- Submission deemed complete. - Priority review requested. Priority review not granted on 2010-Dec-8. - Submission placed in queue in accordance with CDR procedures. Review to be initiated pending the availability of resources. - Submission initiated on 2011-Jan-07
2	Patient group input submission received		2011-Dec-21	2011-Jan-21	- 2010-Dec-21 - Date tentative until submission initiated - 2011-Jan-21 - Patient input due - Patient group submissions received
3	CADTH Reviewers' Reports sent to Manufacturer	45	2011-Mar-24	2011-Mar-24	
4	Comments from Manufacturer on Reviewers' Reports Received by CADTH	7	2011-Apr-04	2011-Apr-04	
5	CEDAC Meeting		2011-May-18	2011-May-18	
6	CEDAC Recommendation *** Sent to Drug Plans, ACP and Manufacturer	5 to 7	2011-May-26	2011-May-26	
7	Embargo Period **** Manufacturers may make a Request for Reconsideration and Drug Plans may make a Request for Clarification of the Recommendation	10	2011-Jun-09	2011-Jun-09	- Request for reconsideration received 2011-Jun-9 New informaion received in Request for Reconsideration - Request for reconsideration not granted 2011-Jun-16 - Review stopped 2011-Jun-16 - Resubmission pending
8 (a)	Final Recommendation sent to Drug Plans, ACP, and Manufacturer (No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved)	5			
	OR				
8 (b)	Clarification and Final Recommendation sent to Drug Plans, ACP, and Manufacturer (Clarification Requested, no Request for Reconsideration made)	5			
	OR				
8 (c)	Placed on CEDAC Agenda For Reconsideration (At Manufacturer's request)	25 Depends on Meeting Dates			
9	Final Recommendation sent to Drug Plans, ACP, and Manufacturer	5			

* Refer to the Procedure for Common Drug Review on the Common Drug Review section of www.cadth.ca for more details.

** The Formulary review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CEDAC meeting schedule, which is posted on www.cadth.ca.

*** The Procedure for Common Drug Review, section 8.3.3a, states "…the CEDAC recommendation will be sent to the Manufacturer, ACP and to the drug plans within five (5) to seven (7) business days following the CEDAC meeting…". The original target date is based on five (5) business days.

**** The Recommendation is held in confidence and not acted upon until after CADTH has issued the notice of Final Recommendation.

This submission status report reflects updates as of Thursday noon.